EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib are first-line treatments for advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations, and have been reported to improve the clinical outcome and quality-of-life of patients with this malignancy [1-4].